Thomas D.Y. Chung

发表

Scheme 3, General synthetic strategy for analogs of ML261

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Table 3, Probe and Analog Submissions to MLSMR (Evotec) for P. falciparum G-6PDH antagonists

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Figure 4, Screening and Hit advancement flowchart

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2013 .

Figure A6E, LCMS purity data at 214 nm for ML291 2nd batch –submitted to the MLSMR (SID 134228465, CID 52940465); LCMS retention time: 3.125 min; purity at 214 nm = 97.5%

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Scheme 1, Proposed Synthesis of MLS-0092727

Thomas D.Y. Chung, Eduard Sergienko, Derek Stonich, 2010 .

Figure 1, Key SAR for our first library

Darren Finlay, Kristiina Vuori, Robert Ardecky, 2011 .

Figure 3, Profiling of the 21 most active VHR screening hits at 20 µM against VHR (AID-2074) & HePTP (AID-2082)

Stefan Vasile, Ying Su, Thomas D.Y. Chung, 2010 .

Table 2, Submission information on Probe and analogs

Thomas D.Y. Chung, Eduard Sergienko, Derek Stonich, 2010 .

Table 4, Probe and Analog Submissions to MLSMR (BioFocus DPI) for Gli-Sufu Antagonist ML340

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Figure 9, Structure of confirmed most attractive screening hits

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Table 4, Summary of the existing probes and the corresponding commercial vendors

Thomas D.Y. Chung, Eduard Sergienko, Derek Stonich, 2010 .

Figure 7, Hit triage for Lipid Droplets

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure 1, [Comparative data on (1) probe, (2) similar compound structures (establishing SAR) and (3) prior probes].

Ying Su, Thomas D.Y. Chung, Derek Stonich, 2010 .

[Table, Primary Screen Protocol].

Susanne Heynen-Genel, Michelle Sauer, Shenghua Shi, 2010 .

Table 1, Listing of all Assays and AIDs for this project

Susanne Heynen-Genel, Shenghua Shi, Thomas D.Y. Chung, 2010 .

Figure 1: [Example of data from a...].

Thomas D.Y. Chung, Layton H. Smith, David B. Terry, 2015 .

Scheme 1, Synthesis of ML307, conditions

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Comparison of Automation Equipment in High Throughput Screening

Thomas D.Y. Chung, Ilona Kariv, P. J. Bouchard, 1998 .

Table 2, Structures and data for the lead triazoles

Thomas D.Y. Chung, Eduard Sergienko, Derek Stonich, 2010 .

Table 5A, Submission information on Probe 1: CID2286812 and analogs

Susanne Heynen-Genel, Michelle Sauer, Shenghua Shi, 2010 .

Table 8, Comparative data for probe specificity

Mahesh Peddibhotla, Thomas D.Y. Chung, Eduard Sergienko, 2010 .

Table 4, Probe and Analog Submissions to MLSMR (BioFocus DPI) for UBC13 Inhibitors

Santhi Ganji, Ian Pass, Robert Ardecky, 2013 .

Table 3, Pharmacologic Properties of MLS-01014097, MLS-0107074

Layton H. Smith, Thomas D.Y. Chung, Eduard Sergienko, 2010 .

Table 5, Probe and Analog Submissions to the MLMR (BioFocus DPI)

Susanne Heynen-Genel, Thomas D.Y. Chung, Palak Gosalia, 2010 .

Table 5, Submission of Probe and analogs

Darren Finlay, Kristiina Vuori, Robert Ardecky, 2011 .

Figure A6F, HRMS data for ML291 2nd batch –submitted to the MLSMR (SID 134228465, CID 52940465); HRMS m/z calculated for C16H17ClN3O6S [M + H+]: 414.0521, found 414.0522

Stefan Vasile, Eigo Suyama, Anthony B. Pinkerton, 2013 .

Table 1, SAR results generated using analogue-by-catalogue (ABC)

Layton H. Smith, Thomas D.Y. Chung, Eduard Sergienko, 2010 .

Table 3, CID 56639556 [ML307] MLS-0471611

Santhi Ganji, Ian Pass, Robert Ardecky, 2014 .

Scheme 1, Synthesis of ML377

Susanne Heynen-Genel, Stefan Vasile, Eigo Suyama, 2015 .

[Figure], Critical Path Flowchart for KOR Antagonist Project

Susanne Heynen-Genel, Thomas D.Y. Chung, Palak Gosalia, 2010 .

Scheme 1, Synthesis of ML304

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Table 5, Submission information on Probe 2 and analogs

Ying Su, Thomas D.Y. Chung, Derek Stonich, 2010 .

Scheme 1, Synthesis of ML261, conditions

Jiwen Zou, Santhi Ganji, Ian Pass, 2013 .

Scheme 1, Synthesis of ML260

Jiwen Zou, Santhi Ganji, Ian Pass, 2013 .

Figure 10, SAR strategy for Scaffold I

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure 2, Probe analogs variations: 3 regions were explored by chemical synthesis: the left hand side (LHS), linker and right hand side (RHS)

Ying Su, Thomas D.Y. Chung, Derek Stonich, 2010 .

Table 4, Submission of Probe and 5 analogs to the MLSMR

Stefan Vasile, Thomas D.Y. Chung, Eduard Sergienko, 2010 .

Table 5, Submission of Probe and 6 analogs to the MLSMR (MLSMR)

Mahesh Peddibhotla, Thomas D.Y. Chung, Eduard Sergienko, 2010 .

Table 5B, Submission information on Probe#2: CID1542103 and analogs

Susanne Heynen-Genel, Michelle Sauer, Shenghua Shi, 2010 .

[Table, A tabular presentation summarizing known probe properties (computed properties, must match from PubChem)].

Susanne Heynen-Genel, Michael Vicchiarelli, Shenghua Shi, 2011 .

[Table, Image Acquisition and Analysis].

Susanne Heynen-Genel, Michelle Sauer, Shenghua Shi, 2011 .

Figure 2, Key SAR for our second library

Darren Finlay, Kristiina Vuori, Robert Ardecky, 2011 .

Table 8, Comparative Downstream assays by Assay Provider for CID9581011

Susanne Heynen-Genel, Michelle Sauer, Shenghua Shi, 2011 .

[Table], EXPERIMENTAL RESULTS FOR SID 123083137 ON OTHER TARGETS

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Figure 5, Screening results and Hit validation

John C. Reed, Santhi Ganji, Ian Pass, 2011 .

Table 8, Comparison of prior art and current probe

Susanne Heynen-Genel, Thomas D.Y. Chung, Palak Gosalia, 2010 .

Table 5, Potencies of key screening hit scaffolds

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure 1, Summary of the hit structures for the KOP antagonist project

Susanne Heynen-Genel, Thomas D.Y. Chung, Palak Gosalia, 2010 .

Scheme 1, Synthetic scheme

Thomas D.Y. Chung, Eduard Sergienko, Derek Stonich, 2010 .

Table 9, Comparative summary of two current probes CID5236771 & CID44601470 to literature examples

Susanne Heynen-Genel, Thomas D.Y. Chung, Palak Gosalia, 2010 .

Table 4, Submission information on Probe 1 and analogs

Thomas D.Y. Chung, Michael Hedrick, Eduard Sergienko, 2010 .

Table 3, Probe and Analog Submissions to MLSMR (BioFocus DPI) for APJ Antagonists

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Scheme 1, Synthesis of ML276

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Scheme 2, Synthesis of ML262, conditions

Jiwen Zou, Santhi Ganji, Ian Pass, 2014 .

Figure A6C, LCMS purity data at 214 nm for ML291 1st batch (SID 123083137, CID 52940465); LCMS retention time: 3.074 min; purity at 214 nm = 95.4%

Stefan Vasile, Eigo Suyama, Michael Vicchiarelli, 2013 .

Table 1, PubChem Assay Summaries for Probe project

Darren Finlay, Robert Ardecky, Thomas D.Y. Chung, 2010 .

Selective HePTP Inhibitors: Probe 1

Thomas D.Y. Chung, Eduard Sergienko, Russell Dahl, 2010 .

Figure 3, Flowchart Summary of Screening Results

Stefan Vasile, Eigo Suyama, Ying Su, 2011 .

Figure 2, The GPR35 Antagonist Probe Flowchart summarizes the compound triage and decision tree for advancement of the compounds

Susanne Heynen-Genel, Michelle Sauer, Shenghua Shi, 2010 .

Table 3, Probe and Analog Submissions to MLSMR (Evotec) for TAG inhibitors

Susanne Heynen-Genel, Eigo Suyama, Layton H. Smith, 2015 .

Table 5, Exploration of the left hand side of the lead structure

Thomas D.Y. Chung, Eduard Sergienko, Derek Stonich, 2010 .

Screen Compounds Singly: Why Muck It Up?

Thomas D.Y. Chung, T. Chung, 1998 .

Selective Bcl-2 Inhibitor Probes

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2013 .

Assay Miniaturization for Ultra-High Throughput Screening of Combinatorial and Discrete Compound Libraries: A 9600-Well (0.2 Microliter) Assay System

Thomas D.Y. Chung, Kevin R. Oldenburg, Ji-Hu Zhang, 1998 .